An interventional study of PTNS de verum and PTNS placebo in Multiple Sclerosis and Lower Urinary Tract Symptoms, sponsored by University Hospital, Lille. Recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-23.
Sponsored by University Hospital, Lille · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Multiple Sclerosis by University Hospital, Lille — 4 open to participants now, 4 under way, none of them phase 3. Multiple Sclerosis · University Hospital, Lille.
Among the 11 studies in Multiple Sclerosis by University Hospital, Lille, this one is the only one that started in 2021, is one of 4 with no phase, and was the 8th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →4 of the 11 studies in Multiple Sclerosis by University Hospital, Lille are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Lille · Sites in France
Ages 18–65
University Hospital, Lille · Sites in France
Ages 18–55
University Hospital, Lille · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2021.
This study's planned enrollment of 68 is above the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 134 across the 4 interventional studies, 115 across the 7 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Multiple Sclerosis by University Hospital, Lille, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The present trial is designed to assess the efficacy and safety of transcutaneous tibial neuro-stimulation (TTNS) in improving bladder emptying in multiple sclerosis (MS) patients.
Patients presenting with MS and performing clean intermittent self-catheterization (CISC) to empty the bladder in the context of voiding dysfunction, will be eligible.
Included patients will be randomly assigned to two distinct arms
Efficacy in improving voiding dysfunction will be assessed 12 weeks after randomization using the BVE ratio (Bladder Voiding Efficiency) = Ratio of urine volume / total bladder volume.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patient with one or more bladder diverticulum(s) Patient with unilateral or bilateral renal Patient with unilateral or bilateral vesico-ureteral reflux Patient with impaired renal function ( according to CKD-EPI \< 60 ml/min/1.73m2) Patient with a metallic prosthesis on the lower limb Patient with a Pacemaker Pregnant patient
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be treated with transcutaneous tibial neuro-stimulation with one 30-minute session daily for a period of 12 weeks.
Device: PTNS de verum
Patients will be treated with placebo (i.e. no current) transcutaneous tibial neuro-stimulation for 30 consecutive minutes daily for 12 weeks (same treatment regimen as the experimental group).
Device: PTNS placebo
The device will be set to program P-4: Frequency 20Htz, Pulse duration = 200 µs. The amplitude (Volt) will be adjusted by the patient according to the feeling.
Also known as: Peristim Pro (CEFAR-COMPEX®)
The device will be set to program P-4: Frequency 20Htz, Pulse duration = 200 µs. A resistor will be incorporated in the device to block the passage of electric current
Also known as: Peristim Pro (CEFAR-COMPEX®
BVE ratio (Bladder Voiding Efficiency) = Ratio of urine volume / total bladder volume
BVE will be measured during the multi-channel urodynamic study
Time frame: At 12 weeks after randomization
Maximal flow rate (mL/s) on multi-channel urodynamic study
Maximal flow rate will be measured during the multi-channel urodynamic study
Time frame: At baseline, At 12 weeks after randomization
Post-void residual volume (mL) on multi-channel urodynamic study
Post-void residual volume will be measured during the multi-channel urodynamic study
Time frame: At 12 weeks after randomization
Maximal detrusor pressure during micturition (cmH2O) on multi-channel urodynamic study
Maximal detrusor pressure during micturition will be measured during the multi-channel urodynamic study
Time frame: At 12 weeks after randomization
Mean voided volume (mL) on a three-day ambulatory measure
Mean voided volume will be measured using an ambulatory flowmeter (Homeflow®) during three consecutive days
Time frame: At 12 weeks after randomization
Mean maximal flow rate (mL/s) on a three-day ambulatory measure
Mean maximal flow rate will be measured using an ambulatory flowmeter (Homeflow®) during three consecutive days
Time frame: At 12 weeks after randomization
Mean post-void residual volume (mL) on a three-day ambulatory measure
Mean post-void residual volume will be measured using an ambulatory flowmeter (Homeflow®) during three consecutive days.
Time frame: At 12 weeks after randomization
Frequency of patients who were able to stop clean intermittent self-catheterization (PVR < 100 mL)
Mean post-void residual volume will be measured using an ambulatory flowmeter (Homeflow®) during three consecutive days
Time frame: At 12 weeks after randomization
Urinary symptoms self-reported questionnaire (USP)
USP : Urinary Symptom Profile
Time frame: At 12 weeks after randomization
Quality of life self-reported questionnaire (Qualiveen)
Qualiveen
Time frame: At 12 weeks after randomization
Difficulty to perform CISC self-reported questionnaire (ICDQ)
ICDQ : Intermittent Catheterization Difficulty Questionnaire
Time frame: At 12 weeks after randomization
Digestive symptoms self-reported questionnaire (NBD)
NBD : Neurogenic Bowel Dysfunction
Time frame: At 12 weeks after randomization
Digestive symptoms self-reported questionnaire (Wexner)
Wexner questionnaire
Time frame: At 12 weeks after randomization
Sexual symptoms self-reported questionnaire (FSFI)
FSFI (female) : Female Sexual Function Index
Time frame: At 12 weeks after randomization
Sexual symptoms self-reported questionnaire ( MSHQ)
MSHQ (male) : Male Sexual Health Questionnaire
Time frame: At 12 weeks after randomization
Frequency of patients with detrusor overactivity on multi-channel urodynamic study
Detrusor overactivity will be objectify during the multi-channel urodynamic study
Time frame: At 12 weeks after randomization
Filling volume (mL) at first detrusor unhibited contraction on multi-channel urodynamic study - If detrusor overactivity.
Filling volume at first detrusor unhibited contraction will be measured during the multi-channel urodynamic study.
Time frame: At 12 weeks after randomization
Maximal detrusor pressure (cmH2O) on multi-channel urodynamic study - If detrusor overactivity.
Maximal detrusor pressure will be measured during the multi-channel urodynamic study
Time frame: At 12 weeks after randomization
Maximal cystomanometric capacity (cmH2O) on multi-channel urodynamic study
Maximal cystomanometric capacity will be measured during the multi-channel urodynamic study
Time frame: At 12 weeks after randomization
Frequency of adverse events occurring during the 12-week follow-up
Adverse events will be exhaustively listed
Time frame: Measured 12 weeks after randomization
Started Dec 2021 (actual). Primary completion is estimated for Jun 2026, 54 months after the start.
Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 54 months is above that.
Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.